{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', '(GOG) impression that the older agents (ifosfamide, mitomycin, and 5-fluoruracil) are less', 'commonly used in contemporary practice for cervical cancer.', '4.', 'STUDY VARIABLES', '4.1.', 'Demographic and Baseline Characteristics', 'Baseline characteristics will include standard demography (eg, age, race, weight, and height) and', 'disease characteristics, tumor histology (squamous versus adenocarcinoma/adenosquamous), and', 'geographic region, as well as medical and oncology history. Oncologic history will include prior', 'treatments with platinum agents, paclitaxel, and bevacizumab (or reason why paclitaxel or', 'bevacizumab was not given previously).', '4.2.', 'Primary and Secondary Enppoints', '4.2.1.', 'Primary Endpoint', 'The primary endpoint is OS, defined as the time from randomization to the date of death. A patient', 'who has not died will be censored at the last known date of contact.', '4.2.2.', 'Secondary Enppoints', 'The key secondary endpoints are PFS and ORR.', 'Progression-free survival will be defined as the time from randomization to the date of the first', 'documented tumor progression using RECIST 1.1, or death due to any cause. Patients will be', 'censored according to rules listed below:', '1.', 'Patients who do not have a documented tumor progression or death will be censored on the', 'date of their last evaluable tumor assessment.', '2. Patients who do not have any evaluable tumor assessments after randomization and do not', 'die will be censored on the date of randomization.', 'Overall response rate will be defined as the number of patients with a best overall response of', 'confirmed CR or PR divided by the number of patients in the efficacy analysis set. Best overall', 'response will be defined as the best overall response between the date of randomization and the', 'date of the first objectively documented progression or the date of subsequent anti-cancer therapy,', 'whichever comes first.', '4.2.3.', 'Other Secondary Enppoints', 'Other secondary endpoints will include DOR and QOL. Duration of response will be defined as', 'the time between the date of first response (CR or PR) to the date of the first documented tumor', 'progression (per RECIST 1.1) or death due to any cause. Quality of life will be measured by the', 'EORTO QLQ-C30.', 'Other secondary endpoints will also include the safety and tolerability of cemiplimab. To evaluate', 'the safety and tolerability of cemiplimab IC chemotherapy, the incidence of AEs, serious adverse', 'events (SAEs), deaths, and laboratory abnormalities will be assessed.', 'Regeneron Pharmaceuticals, Inc.', 'Page 43 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', '4.3.', 'Exploratory Endpoints', '4.3.1.', 'Pharmacokinetic Variables', 'Cemiplimab concentrations in the serum will be assessed at multiple time points throughout the', 'treatment and follow-up periods.', 'Pharmacokinetic variables may include, but are not limited to, the following:', 'Ceoi - concentration at end of infusion', 'Ctrough', '4.3.2.', 'Anti-Drug Antibody Variables', 'Anti-drug antibody (ADA) variables include status of ADA response and titer as follows:', 'Treatment-emergent ADA response - defined as any positive response post-treatment', 'when baseline results are negative or missing', 'Treatment-boosted ADA response - defined as any post treatment ADA response that', 'is at least 9-fold over baseline titer levels when baseline results are positive', 'Titer values (titer value category)', '- Low (titer <1,000)', '- Moderate (1,000< titer <10,000)', '- High (titer >10,000)', 'Samples that are positive in the ADA assay may be analyzed for the neutralizing', 'activities', '4.3.3.', 'Other Exploratory Variables', 'Relationships between efficacy endpoints and candidate biomarkers in tumor and peripheral blood', 'will be described.', '5.', 'STUDY DESIGN', '5.1.', 'Study Description and Duration', 'This is an open-label, randomized, multi-center, phase 3 trial comparing cemiplimab versus IC of', 'chemotherapy in patients with recurrent or metastatic cervical cancer. Approximately 590 patients', 'will be randomized to either the experimental cemiplimab treatment arm or the IC of chemotherapy', 'control treatment arm. In the experimental group, cemiplimab will be administered as a flat dose', 'of', '350 mg Q3W. In the control group, IC chemotherapy options are in 4 classes:', '(1) antifolate - pemetrexed, (2) topoisomerase 1 inhibitor - topotecan or irinotecan, (3) nucleoside', 'analogue - gemcitabine, and (4) vinca alkaloid - vinorelbine. A schematic diagram of the study', 'design is presented in Figure 2. The only chemotherapy treatments allowed in the control arm are', 'any of the 5 drugs that are listed as IC options. Other agents in these classes are not permitted in', 'this study.', 'Regeneron Pharmaceuticals, Inc.', 'Page 44 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}